XOLREMDI

Growth

mavorixafor

NDAORALCAPSULEPriority Review
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
7

Mechanism of Action

CXC Chemokine Receptor 4 Antagonists

Pharmacologic Class:

CXC Chemokine Receptor 4 Antagonist

Clinical Trials (5)

NCT06858696Phase 1Recruiting

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Started Feb 2025
48 enrolled
Hepatic Insufficiency
NCT06914869Phase 1Completed

Drug-Drug Interaction Potential of Mavorixafor

Started Feb 2025
38 enrolled
Healthy Participants
NCT06056297Phase 3Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Started Jun 2024
176 enrolled
Neutropenia
NCT04154488Phase 1/2Completed

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Started Oct 2021
32 enrolled
Neutropenia
NCT04274738Phase 1Completed

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Started Apr 2020
16 enrolled
Waldenstrom's Macroglobulinemia

Loss of Exclusivity

LOE Date
Dec 11, 2038
155 months away
Patent Expiry
Dec 11, 2038
Exclusivity Expiry
Apr 26, 2031

Patent Records (5)

Patent #ExpiryTypeUse Code
10953003
Dec 14, 2036
Product
10610527
Dec 22, 2036
U-3932
11219621
Dec 22, 2036
U-3932
10548889
Dec 11, 2038
Product
11045461
Dec 11, 2038
Product